Samir Patel
Optometrist · Beaumont, TXNPI 1922263961
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 24.8% of the total. Reporting peaked in 2024 at $6,499 and has fallen 60.1% since, to $2,593 in 2025. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $58.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$3K
- Coopervision Inc.$3K
- Bausch & Lomb Americas Inc.$2K
- Alcon$2K
- Topcon Healthcare, Inc.$1K
- Johnson & Johnson Vision Care, Inc.$877
- plus $1K from 13 others
Across 11 payments — averaging $10,502 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coopervision Inc.$115K
- Tarsus Pharmaceuticals, Inc.$600
What the payments were for
- Consulting fees$3,95029%
- Speaking & faculty fees$5754%
- Travel & lodging$2,82421%
- Food & beverage$6,28446%
- Education$490%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 13 | $3,394 |
| Coopervision Inc. | 34 | $2,573 |
| Bausch & Lomb Americas Inc. | 53 | $2,374 |
| Alcon | 47 | $1,908 |
| Topcon Healthcare, Inc. | 2 | $1,100 |
| Johnson & Johnson Vision Care, Inc. | 32 | $877 |
| Oyster Point Pharma, Inc. | 22 | $636 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $219 |
| AbbVie(2 entities) | 6 | $143 |
| EMD Serono, Inc. | 2 | $101 |
| Dompe US, Inc. | 3 | $81 |
| Glaukos Corporation | 3 | $77 |
| Synergeyes, Inc. | 4 | $72 |
| Harrow Eye, LLC | 3 | $56 |
| Lombart Brothers, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$1,465
- XDEMVY$1,139
- Dailies Aqua Comfort Plus$751
- DAILIES TOTAL1 Multifocal$751
- AIR OPTIX$751
- DAILIES$322
- ALDEN SCLERAL ZENLENS$127
- Clariti Contact Lens$118
- INFUSE$111
How this compares
$13,702 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 17 | $30,279 |
| VyzultaLatanoprostene Bunod | 31 | $15,142 |
| Latanoprost | 34 | $494 |
| Timolol Maleate | 12 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $3,394 | $30,27917 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $2,374 | $15,14231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Beaumont
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
- Jill AutryBellaire$171K
- Stacie VirdenWaco$164K
- Richard PotvinBurleson$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.